High levels of mtp53 are found in over 50% of all human tumors from patient samples.1 Somatic mutations in only three genes occur at greater than 10% incidence across all different subtypes of breast cancers, and one of these is mutation in the TP53 gene.2 More than 80% of TNBCs contain mtp53 protein.2–4 As far back as 1984 it was reported that the “oncogene” p53 cooperated with ras to transform cells;28,29 however, we still do not use mtp53 as a diagnostic or treatment-mediated paradigm. This evidence concerns the gene TP53 and breast cancer.